January 7, 2019 from The Permanente Journal
Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a “high.” A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system.
Anxiety scores decreased within the first month in 79.2% of patients and remained decreased during the study duration. Sleep scores improved within the first month in 48 66.7% of patients.
